Back to results
US 2022/0017863 A1Published application
Sirt2-ablated chimeric t cells
OwnerSungjune Kiminventor
Life of this patent
Estimating the term…
Abstract
Disclosed herein are lymphocytes for use in adoptive cell transfer that have chemically- or genetically-inhibited Sirt2 expression. Also disclosed are methods of inhibiting or ablating Sirt2 expression in a T cell ex vivo. Also disclosed are methods of treating cancer in a subject that involves collecting lymphocytes, such as tumor infiltrating lymphocytes (TILs), from the subject, treating the lymphocytes ex vivo to inhibit Sirt2 expression, and transferring the modified lymphocytes back to the subject.
Claims10
A method comprising
- (a) collecting lymphocytes from a subject with cancer;
- (b) treating the lymphocytes with a Sirt2 inhibitor or genetically modifying the lymphocytes to inhibit or ablate Sirt2 expression.
Dependencies are inferred from the claim text.